BeyondSpring Inc. reports developments tied to its clinical-stage oncology pipeline, led by Plinabulin, an immune-modulating cancer therapy studied in non-small cell lung cancer and other indications. Recurring updates cover DUBLIN-3 data analyses, Plinabulin combinations with docetaxel, checkpoint inhibitors and antibody-drug conjugates, and presentations at oncology and immuno-oncology medical meetings.
Company news also includes periodic financial results, annual-report announcements, capital and corporate updates, and disclosures related to BeyondSpring’s equity interest in SEED Therapeutics and molecular glue degrader programs. These updates connect the company’s research activity, clinical-development strategy and financing actions with its public-company reporting cycle.
BeyondSpring, a biopharmaceutical company focusing on innovative cancer therapies, announced the pricing of a public offering of 1,930,000 ordinary shares at $13.00 each, alongside a private placement of 384,615 shares to Decheng Capital. The total gross proceeds are projected to be approximately $30.1 million. Funds will support the commercialization of Plinabulin and further clinical development. The public offering is set to close on June 23, 2020, while the private placement is expected on July 2, 2020.
BeyondSpring Inc. (BYSI) announced a public offering of ordinary shares, expected to raise funds for the commercialization of its lead therapy, Plinabulin, and to support ongoing clinical development. The offering also includes a private placement with Decheng Capital. Jefferies and William Blair are acting as joint book-running managers. The offering is subject to market conditions and may not proceed as planned. BeyondSpring is focused on developing innovative immuno-oncology therapies, with Plinabulin currently in multiple Phase 3 clinical trials.
BeyondSpring (NASDAQ: BYSI) announced positive topline results from the PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta against Neulasta alone. The primary endpoint of reducing Grade 4 neutropenia was met (p0.01), along with key secondary endpoints for the duration of severe neutropenia (p<0.05). The trial showed that the combination offers early protection during the first chemotherapy cycle, potentially addressing a significant unmet medical need in cancer care. A conference call will provide further insights.
BeyondSpring (NASDAQ: BYSI) announced promising results from the PROTECTIVE-2 Phase 2 trial, showcasing its lead asset Plinabulin in combination with Neulasta. The study revealed a 72% reduction in chemotherapy dose adjustments, with only 6.3% of patients needing dose reduction compared to 22.7% in the Neulasta-only group. Additionally, no patients downgraded their chemotherapy regimen in the Plinabulin group, potentially leading to better long-term survival outcomes. The improvements address the critical issue of Grade 4 neutropenia prevalent during high-risk chemotherapy.
BeyondSpring (NASDAQ: BYSI) announced that its Phase 3 Dublin-3 clinical trial for Plinabulin in non-small cell lung cancer (NSCLC) has received a favorable recommendation from the Data & Safety Monitoring Board (DSMB) after reviewing data from over 500 patients. The trial aims to evaluate the efficacy of Plinabulin combined with docetaxel compared to docetaxel alone in second- and third-line EGFR wild-type NSCLC patients. Previous Phase 2 results showed that this combination significantly extends overall survival while reducing severe neutropenia rates.
Summary not available.
Summary not available.
Summary not available.